{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:48:41Z","timestamp":1779230921936,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cca.2024.119995","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:38:42Z","timestamp":1728506322000},"page":"119995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical implications of opioid parent-metabolite ratios"],"prefix":"10.1016","volume":"565","author":[{"given":"Hsuan-Chieh","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Keebaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew N.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey S.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cca.2024.119995_b0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1373\/jalm.2017.024893","article-title":"Challenges in interpreting unexpected urine drug test results","volume":"2","author":"Heger","year":"2018","journal-title":"J. Appl. Lab. Med."},{"issue":"22","key":"10.1016\/j.cca.2024.119995_b0010","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.4155\/bio.13.244","article-title":"The challenges of LC-MS\/MS analysis of opiates and opioids in urine","volume":"5","author":"French","year":"2013","journal-title":"Bioanalysis"},{"issue":"3","key":"10.1016\/j.cca.2024.119995_b0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.chc.2016.02.005","article-title":"Objective testing: urine and other drug tests","volume":"25","author":"Hadland","year":"2016","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.cca.2024.119995_b0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jsat.2017.10.002","article-title":"High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio","volume":"83","author":"Accurso","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"issue":"21","key":"10.1016\/j.cca.2024.119995_b0025","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1007\/s00216-023-04711-w","article-title":"Advances in testing for sample manipulation in clinical and forensic toxicology - Part A: urine samples","volume":"415","author":"Wissenbach","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.cca.2024.119995_b0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jmsacl.2023.02.007","article-title":"Bridging the gap: The critical role of laboratory developed tests in clinical toxicology","volume":"28","author":"Noguez","year":"2023","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"10.1016\/j.cca.2024.119995_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123438","article-title":"A Second-generation opioid LC-MS\/MS assay improves laboratory workflow and capacity","volume":"1210","author":"Liao","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"6","key":"10.1016\/j.cca.2024.119995_b0040","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1097\/ADM.0000000000000676","article-title":"Urinary buprenorphine norbuprenorphine and naloxone concentrations and ratios: review and potential clinical implications","volume":"14","author":"Warrington","year":"2020","journal-title":"J. Addict. Med."},{"issue":"8","key":"10.1016\/j.cca.2024.119995_b0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jat\/bkw092","article-title":"Urine creatinine concentrations in drug monitoring participants and hospitalized patients","volume":"40","author":"Love","year":"2016","journal-title":"J. Anal. Toxicol."},{"issue":"2","key":"10.1016\/j.cca.2024.119995_b0050","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.cca.2024.119995_b0055","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1373\/jalm.2017.024786","article-title":"Interpretation of pain management testing results using case examples","volume":"2","author":"Sobolesky","year":"2018","journal-title":"J. Appl. Lab. Med."},{"issue":"7","key":"10.1016\/j.cca.2024.119995_b0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jat\/24.7.530","article-title":"Identification of hydrocodone in human urine following controlled codeine administration","volume":"24","author":"Oyler","year":"2000","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/j.cca.2024.119995_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/30.1.1","article-title":"Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine","volume":"30","author":"Cone","year":"2006","journal-title":"J. Anal. Toxicol."},{"issue":"1","key":"10.1016\/j.cca.2024.119995_b0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/psp4.12735","article-title":"Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers","volume":"11","author":"Duflot","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"4","key":"10.1016\/j.cca.2024.119995_b0075","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/clinchem\/hvaa317","article-title":"Unexpected presence of an unusual opioid in a patient with chronic pain","volume":"67","author":"Phipps","year":"2021","journal-title":"Clin. Chem."},{"issue":"17","key":"10.1016\/j.cca.2024.119995_b0080","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2017.10910","article-title":"Interpretation of Urine Drug Screens: Metabolites and Impurities","volume":"318","author":"Nagpal","year":"2017","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.cca.2024.119995_b0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10550887.2010.509277","article-title":"Advanced urine toxicology testing","volume":"29","author":"Tenore","year":"2010","journal-title":"J. Addict. Dis."},{"issue":"7","key":"10.1016\/j.cca.2024.119995_b0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/jat\/bkad054","article-title":"Pastry precautions: Poppy seed-containing products cause significant positive results in urine drug tests","volume":"47","author":"Wilson","year":"2023","journal-title":"J. Anal. Toxicol."},{"issue":"7","key":"10.1016\/j.cca.2024.119995_b0095","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1526-4637.2012.01350.x","article-title":"Interpretation of urine drug testing in pain patients","volume":"13","author":"Pesce","year":"2012","journal-title":"Pain Med."},{"issue":"1","key":"10.1016\/j.cca.2024.119995_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/33.1.1","article-title":"Normalization of urinary drug concentrations with specific gravity and creatinine","volume":"33","author":"Cone","year":"2009","journal-title":"J. Anal. Toxicol."},{"issue":"7","key":"10.1016\/j.cca.2024.119995_b0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jat\/bkab113","article-title":"Norbuprenorphine interferences in urine drug testing LC-MS-MS confirmation methods from quetiapine metabolites","volume":"46","author":"Munoz-Munoz","year":"2022","journal-title":"J. Anal. Toxicol."},{"issue":"6 Suppl","key":"10.1016\/j.cca.2024.119995_b0110","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpainsymman.2012.08.013","article-title":"Opioid therapies and cytochrome p450 interactions","volume":"44","author":"Gudin","year":"2012","journal-title":"J. Pain Symptom Manage."},{"issue":"9","key":"10.1016\/j.cca.2024.119995_b0115","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jat\/bkab123","article-title":"Urinary pharmacokinetics of immediate and controlled release oxycodone and its phase I and II metabolites using LC-MS-MS","volume":"46","author":"Truver","year":"2023","journal-title":"J. Anal. Toxicol."},{"issue":"3","key":"10.1016\/j.cca.2024.119995_b0120","first-page":"460","article-title":"Estimates of drug metabolism using drug excretion concentrations","volume":"53","author":"Cua","year":"2023","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"5","key":"10.1016\/j.cca.2024.119995_b0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00007691-200310000-00015","article-title":"Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse","volume":"25","author":"von Euler","year":"2003","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.cca.2024.119995_b0130","first-page":"671","article-title":"Letter to editor: observations of deception in urine drug testing","volume":"53","author":"Cua","year":"2023","journal-title":"Ann. Clin. Lab. Sci."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124022484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124022484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:02:30Z","timestamp":1741064550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124022484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"alternative-id":["S0009898124022484"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119995","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of opioid parent-metabolite ratios","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119995"}}